OUHSC Research News – Monday, April 24, 2023
Notices and Reminders
Reminder: ORA would like to provide a reminder that any general or proposal-specific inquiries (what/when to route, information on the form such as participants, attachments, etc.) should be sent to your Sponsored Programs Administrator (SPA) in ORA. If unsure, visit the ORA Website to determine who that is: https://research.ouhsc.edu/research-administration/find-sponsored-program-administrators
If you are unsure of who to contact in ORA or need general triaging, please send your inquiry to hscora@OUHSC.edu. This is the only general mailbox used for triaging questions.
Please send any SoonerTrack system-specific inquiries such as workflow, stuck forms, user access, etc. to SoonerTrack Help Desk at soonertrackhelpdesk@ouhsc.edu. And don’t forget about the SoonerTrack support site! https://research.ouhsc.edu/research-administration/soonertrack-ii-support
Reminder: Please be reminded that anyone who is OUHSC personnel and has effort on the grant needs to be added to the Participants grid on the SoonerTrack Request Form. All the information included in the Participants grid (e.g. participant type, name, total effort %, etc.) must match the grant. Business Managers retain primary responsibility for ensuring that all this information is correct.
Workshops and Seminars
The Ins and Outs of Participant Support Costs
Date: April 26, 2023
Time: 10:00 -11:00 am
Description: The Grants and Contracts Accounting Office (GCA) and the Office of Research Administration (ORA) will be hosting a virtual workshop to address fundamental concepts related to participant support costs.
Participant support costs are payments to individuals for training through a workshop, conference, seminar, or other short term instructional or information sharing activity that is supported by a sponsored award. This workshop will provide attendees with an understanding of what participant support costs are, who can and cannot be a participant, allowable vs. unallowable costs, etc.
Registration: This is a Zoom event. Registrants will receive the Zoom link prior to the event. Please register here.
Questions: Should you have any questions or need more information, please contact Sogol Rasouli at sogol-rasouli@ouhsc.edu.
The USF Summer Grant Writing Workshops
Date: Jun 5, 2023 - Jul 28, 2023
Description: The USF Summer Grant Writing Workshops program is tailored for early career grant seekers of all disciplines. At the core of this course is to advance the understanding of how to prepare a clear, comprehensive, compelling grant proposal. Participants are encouraged to identify a grant opportunity early in the program, draft a proposal, and participate in mock peer review.
This is an 8-week workshop series. It will be offered in a virtual format. Hosted, recorded sessions will be provided to registered participants.
Registration: https://grant.catalog.instructure.com/browse/all/grants/courses/summer-grant-writing-workshops-program-2023-2501
OUHSC Funding Opportunities
NEW! NIH Phase 1 COBRE (P20) call for proposals - OUHSC is now eligible to submit one new Phase 1 COBRE application for the January 30, 2024 deadline. In order to select the most competitive PI and research theme for this COBRE application there will be an internal competition as described in the Guidelines. OUHSC internal deadline is May 12,2023. Please see attached Call for Proposals for details and link to COBRE Guidelines.
New Clinical Study Opportunities
Please note this is NOT a solicitation for study subjects
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
- Janssen_Post-ACS Survey_Protocol 70033093ACS3003
- OG-6219-P001_Organon_Endometriosis_Global_13Mar23_GSID
- Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
- Target population: adult patients with MGFA Class II to IVa gMG
Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
Request for applications: Genetic CRISPR Screening Pilot Award Program from the Oklahoma Nathan Shock Center on Aging and Oklahoma Center for Therapeutic Sciences
The Oklahoma Nathan Shock Center on Aging (NSC) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Pilot Awards in target and pathway discovery in cell-based models of aging and age-associated disease using high throughput screening and arrayed sgRNA CRISPR technologies. Please see the attached RFA for more details.
Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).
- Astellas Pharma is seeking research related to direct reprogramming to achieve transdifferentiation of cells to another functional type in order to discover therapeutic interventions for degenerative diseases. Direct reprogramming of cells to cell types related to CNS, Lung, Heart, Kidney, Liver, Gut, Skin and Eye are of particular interest; all methods of in vivo reprogramming considered. Cell therapy, cell transplantation, biomaterial-based therapy and CRISPR/Cas systems are out of scope. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26).
- Cumulus Oncology is looking to engage with academics who have highly tumor-restricted antigens or moloclonal or multvalent antibodies that target them with potential for therapeutic activity in cancer. Embryonic cell targets are priority but others considered if sufficient tumor-specific activity to minimize off-target effects. Solid tumors are highest interest but all cancers are within scope. Out of scope: drug repurposing, small molecule, small antibodies, ADC, immunotoxins, radioimmunotherapy, gene therapy and call based therapeutics. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26).
- A global pharmaceutical company is looking to identify novel methods for discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets through passive permeation, endocytosis or via transporters. Novel in vitro assays for prediction of bioavailability/intracellular targeting with proven translation to in vivo models are also of interest. Out of scope: use of well-known cell-penetrating peptides (unless significant innovation is demonstrated) and drug delivery systems/formulation strategies. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26)
- Worwag Pharma is seeking novel research and technology related to the role of Vitamin D in human health and applications for prevention and treatment of deficiency. Approaches of interest include metabolites or analogues, novel combinations, approaches with improved metabolism or mode of action, formulations to improve stability and bioavailability, improved drug delivery systems and self-diagnostic tools and digital solutions. Out of scope: Vitamin D for use in food fortification. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 5/20)
NIH Notices
- Request for Information on AHRQ Plan for Updating the Policy for Public Access to Scientific Publications and Scientific Data Resulting from AHRQ Funding
(NOT-HS-23-011)
- Update to Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies
(NOT-AG-23-017)
- Notice of Informational Webinar for PAR-23-138 "Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed)"
(NOT-GM-23-041)
- Notice of Termination of RFA-TR-22-011 HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21)
(NOT-TR-23-012)
- Notice of Termination of RFA-TR-22-013 Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
(NOT-TR-23-013)
- Notice of Termination of PAR-22-058 Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18)
(NOT-TR-23-014)
- Request for Information (RFI): Inviting Comments and Suggestions on NIHs Herpes Simplex Virus Strategic Plan
(NOT-AI-23-042)
- Notice of Participation of the National Institute on Aging (NIA) in PAR-22-181, "Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)"
(NOT-AG-23-021)
- Notice of NIAMS Withdrawal from PA-20-194 "Parent R21 Exploratory/Developmental Grant, Clinical Trial Required"
(NOT-AR-23-018)
- Notice of NIAMS Withdrawal from PA-20-195 "Parent R21 Exploratory/Developmental Grant, Clinical Trial Not Allowed"
(NOT-AR-23-019)
- Notice of Correction to RFA-CA-22-050, NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)".
(NOT-CA-23-061)
- Notice to Extend the Expiration Date of PAR-20-254: Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
(NOT-HG-23-036)
- Notice to Extend the Expiration Date of PAR-20-255: Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
(NOT-HG-23-037)
- Notice to Extend the Expiration Date of PAR-20-257: Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
(NOT-HG-23-038)
- Notice of Change to Submission Requirements for PAR-22-184: Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
(NOT-NS-23-081)
- Notice of Changes to the PAR-22-081, Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)
(NOT-OD-23-118)
- Notice of Special Interest: Administrative Supplements for HIV/AIDS and Aging Research
(NOT-AG-23-008)
- Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas
(NOT-AR-23-006)
- Notice of Special Interest (NOSI): Administrative Supplements for the Dog Oncology Grant Supplement (DOGS) Program
(NOT-CA-23-059)
- Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology
(NOT-CA-23-060)
- Notice of Special Interest: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
(NOT-DK-23-013)
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- STrengthening Research Opportunities for NIH Grants (STRONG): Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not Allowed)
(PAR-23-144)
Application Receipt Date(s): September 18, 2025
- Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)
(PAR-23-149)
Application Receipt Date(s): March 12, 2026
- Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)
(PAR-23-150)
Application Receipt Date(s): March 12, 2026
- Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
(PAR-23-156)
Application Receipt Date(s): Multiple dates, see announcement.
- Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
(PAR-23-161)
Application Receipt Date(s): May 22, 2023
- Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
(PAR-23-168)
Application Receipt Date(s): May 07, 2026
- Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
(PAR-23-169)
Application Receipt Date(s): August 01, 2025
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
(PAR-23-170)
Application Receipt Date(s): January 07, 2027
- Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
(PAR-23-267)
Application Receipt Date(s): Multiple dates, see announcement.
- Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
(PAR-23-268)
Application Receipt Date(s): June 06, 2025
- Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)
(RFA-AI-23-026)
Application Receipt Date(s): August 02, 2023
- Cancer Immunoprevention Network (CIP-Net) ?Research Projects (UG3/UH3 Clinical Trials Not Allowed)
(RFA-CA-23-029)
Application Receipt Date(s): July 03, 2024
- SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
(RFA-CA-23-034)
Application Receipt Date(s): Not Applicable
- Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
(RFA-CA-23-035)
Application Receipt Date(s): August 21, 2023
- Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)
(RFA-CA-24-005)
Application Receipt Date(s): October 13, 2023
- Ending the HIV Epidemic: Focus on Justice Populations with SUD (R61/R33 Clinical Trial Required)
(RFA-DA-24-015)
Application Receipt Date(s): August 16, 2023
- Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed)
(RFA-DA-24-020)
Application Receipt Date(s): November 13, 2023
- Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)
(RFA-DA-24-021)
Application Receipt Date(s): November 13, 2023
- Ending the HIV Epidemic: Resource Center to Engage Justice-Involved Populations (U24 Clinical Trial Optional)
(RFA-DA-24-022)
Application Receipt Date(s): August 16, 2023
- Ending the HIV Epidemic: Focus on Justice Populations with SUD-Data Coordination and Dissemination Center (UM1 Clinical Trial Optional)
(RFA-DA-24-023)
Application Receipt Date(s): August 16, 2023
- Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
(RFA-DA-24-038)
Application Receipt Date(s): February 14, 2025
- Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
(RFA-ES-23-001)
Application Receipt Date(s): October 02, 2023
- Renewal-Native American Tribes Outreach, Education, and Training to Enhance Food Safety and FSMA Compliance (U01) Clinical Trial Not Allowed
(RFA-FD-23-032)
Application Receipt Date(s): June 20, 2023
- Data Integration and Statistical Analysis Methods (DISAM) (U01 Clinical Trial Not Allowed)
(RFA-HG-23-005)
Application Receipt Date(s): November 20, 2023
- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)
(RFA-NS-23-026)
Application Receipt Date(s): Multiple dates, see announcement.
- Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
(RFA-TR-23-011)
Application Receipt Date(s): May 22, 2023
Other Funding Opportunities
DoD Lung Cancer Research Program (LCRP)
- Career Development Award (CDA)
- Concept Award (CA)
Pre-Application (Letter of Intent): May 2, 2023
Application: May 23, 2023
- Idea Development Award (IDA)
- Translational Research Award (TRA)
Pre-Application (Preproposal): May 10, 2023
Application: August 3, 2023
- Patient-Centered Outcomes and Survivorship Award (PCOSA)
Pre-Application (Letter of Intent): July 20, 2023
Application: August 10, 2023
Link to Full Announcement: https://cdmrp.health.mil/funding/lcrp
Cystic Fibrosis (CF) Foundation
Application Deadline: May 11, 2023
CF Foundation NIH K-Boost Award
Description: This award is designed to provide a $50,000 per year supplement to an NIH K-award that has a CF focus.
Application Deadline: Rolling applications must be submitted online at awards.cff.org.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/cf-foundation-nih-k-boost-award
CF Foundation/NIH K-Unfunded Award
Description: This award is designed to provide support for investigators with meritorious NIH K applications that were not selected for funding as they revise and resubmit.
Application Deadline: Rolling applications must be submitted online at awards.cff.org.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/cf-foundationnih-k-unfunded-award
CF Research Additional Mentoring Program (RAMP)
Description: The RAMP Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.
Application Deadline: Applications must be submitted online at awards.cff.org by May 23, 2023.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/research-additional-mentoring-program-award
The Lung Cancer Research Foundation (LCRF) – Daiichi Sankyo – AstraZeneca Research Grant on Antibody Drug Conjugates
Description: LCRF is pleased to announce a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. This competitive funding mechanism will provide up to $270,000 in funding over a two-year period.
The LCRF - Daiichi Sankyo - AstraZeneca Research Grant on Antibody Drug Conjugates will develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs.
Application Deadline: May 31, 2023
Link to Full Announcement: Complete details including eligibility criteria and application instructions may be found on the LCRF website.
Robert A. Winn Career Development Award (Winn CDA)
Description: The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations. The program collaborates with communities to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. It provides emerging investigators the sponsorship, support, and tools they need to conduct clinical trials that will yield new treatments effective in all populations.
Application Deadline: May 12, 2023
Link to Full Announcement: https://diversityinclinicaltrials.org/application-information . Please see the attached flyers.
DoD Ovarian Cancer Research Program (OCRP)
- Clinical Translational Research Award
- Clinical Trial Award
- Ovarian Cancer Clinical Trial Academy - Leadership Award
Pre-Application: May 26, 2023
Application: July 21, 2023
Link to Full Announcement: https://cdmrp.health.mil/funding/ocrp
DoD Epilepsy Research Program (ERP)
Pre-Application (Letter of Intent): May 19, 2023
Application: June 23, 2023
Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495101
The International Center for Responsible Gaming - REQUEST FOR APPLICATIONS ON RESEARCH ON PRE-COMMITMENT AS A PREVENTION MEASURE TO REDUCE GAMBLING-RELATED HARMS
Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a two-year Large Grant to study the effectiveness of “pre-commitment,” a prevention strategy that encourages gamblers to set limits on money and time spent gambling. Applicants may request up to a total of $75,000 per year for up to two years plus 15 percent in Facilities & Administration costs. Total amount that may be requested is $172,500.
Application Deadline: May 15, 2023
Link to Full Announcement: https://www.icrg.org/information/apply-for-icrg-funding